Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedApr 10, 2019Pantoprazole Sodium Delayed-Release TabletsDiscoloration: Expansion of an earlier recall due to the presence of dark brown discoloration on the edges of the tablets.Jubilant Cadista Pharmaceuticals, Inc. · D-1074-2019Class ITerminatedApr 10, 20198.4% Sodium Bicarbonate InjectionPresence of Particulate Matter; glass particulatesPfizer Inc. · D-1073-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1072-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1071-2019Class IIITerminatedApr 10, 2019Clindamycin InjectionFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1070-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1069-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1068-2019Class IIITerminatedApr 10, 2019Cleocin PhosphateFailed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time pointPfizer Inc. · D-1067-2019Class ITerminatedApr 3, 2019Blue Fusion CapsulesMarketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared ingredients: Sildenafil, Tadalafil, desmethyl carbodenafil, dithiodesmethyl...Ata International Inc · D-1085-2019Class IITerminatedApr 3, 2019Express Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1064-2019Class IITerminatedApr 3, 2019Quick-Care Foam Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1063-2019Class IITerminatedApr 3, 2019Moisturizing Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1062-2019Class IITerminatedApr 3, 2019Advanced Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1061-2019Class IITerminatedApr 3, 2019Gel Hand SanitizerChemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Ecolab Inc · D-1060-2019Class IIITerminatedApr 3, 2019Diclofenac Sodium Topical SolutionDefective Container: firm discovered samples stored horizontally as well as product quality complaints from customers for bottles leaking.Ingenus Pharmaceuticals Llc · D-1058-2019Class IITerminatedApr 3, 2019FayosimFailed Impurities/Degradation Specifications: Out-of-specification results observed in related substance test (Any Other Individual Impurity and Total impurities) in...Lupin Pharmaceuticals Inc. · D-1057-2019Class IITerminatedApr 3, 2019CombigancGMP DeviationsAllergan Sales, LLC · D-1056-2019Class IITerminatedMar 27, 2019Etomidate InjectionSubpotent Drug.Heritage Pharmaceuticals, Inc. · D-1065-2019Class IIOngoingMar 27, 2019Valsartan Tablets 320 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1055-2019Class IIOngoingMar 27, 2019Valsartan Tablets 160 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1054-2019Class IIOngoingMar 27, 2019Valsartan Tablets 80 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1053-2019Class IIOngoingMar 27, 2019Valsartan Tablets 40 mg USPCGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished productsRising Pharmaceuticals, Inc. · D-1052-2019Class IITerminatedMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.Preferred Pharmaceuticals, Inc · D-1051-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1050-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1049-2019Class IIOngoingMar 27, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detectedLegacy Pharmaceutical Packaging LLC · D-1048-2019Class IITerminatedMar 27, 2019Valsartan Tablets USP 160 mgCGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.American Health Packaging · D-1047-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1046-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1045-2019Class IITerminatedMar 27, 2019Losartan Potassium Tablets USP 50 mg 50 TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identifiedAVKARE Inc. · D-1044-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1043-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1042-2019Class IIOngoingMar 27, 2019Losartan Potassium Tablets USPCGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredientCamber Pharmaceuticals Inc · D-1041-2019Class IITerminatedMar 27, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.Macleods Pharma Usa Inc · D-1040-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 160 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1039-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 80 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1038-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 40 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1037-2019Class IIOngoingMar 27, 2019Amlodipine and Valsartan Tablets USP 10mg/160mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1036-2019Class IIOngoingMar 27, 2019Valsartan Tablets USP 320 mgGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Aurobindo Pharma USA Inc. · D-1035-2019Class IITerminatedMar 27, 2019Phenylephrine HClLack of Assurance of SterilityAdvanced Pharma Inc. · D-1034-2019

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.